EuPFI 2021: Development of a Novel Pediatric Belumosudil Oral Suspension
Overview
Belumosudil is an oral selective rho-associated coiled-coil containing protein kinase 2 inhibitor, and an approved treatment for chronic graft-versus-host disease.
Quotient Sciences was approached by a client requiring a belumosudil formulation for a pediatric patient population aged between three months and twelve years.
This development program aimed to develop a suitable, novel belumosudil oral suspension formulation using age-appropriate excipients to be used in a relative bioavailability assessment of the suspension compared to the reference adult tablet formulation.
A liquid belumosudil formulation enabled flexible dosing by varying the dose volume according to the age and/or body weight of the patient.
Download our poster from EuPFI 2021 to see the outcome of this program.